Studies of therapeutic angiogenesis have generally focused on single growth
factor strategies. However, multiple factors participate in angiogenesis.
We evaluated the angiogenic potential of a growth factor mixture (GF(m)) de
rived from bovine bone. The major components of GF(m) (SDS-polyacrylamide g
el electrophoresis, mass spectrometry, and Western blot) include transformi
ng growth factor-beta1-3, bone morphogenic protein-2-7, and fibroblast grow
th factor-1. GF(m) was first shown to induce an angiogenic response in chor
ioallantoic membranes. Next, myocardial ischemia was induced in 21 dogs (am
eroid) that were randomized 3 weeks later to received GF(m) 1 mg/ml (I), GF
(m), 10 mg/ml (II), or placebo (P) (with investigators blinded to condition
s) injected in and adjacent to ischemic myocardium. Dogs were assessed 6 we
eks later using quantitative and semiquantitative measures. There were GF,
concentration-dependent improvements in distal left anterior descending art
ery (LAD) opacification by angiography (P: 0.4 +/- 0.2,I: 1.1 +/- 0.14, II:
1.6 +/- 0.3, angiographic score p = 0.014). Histologically, there was also
concentration-dependent vascular growth response of relatively large vesse
ls (P: 0.21 +/- 0.15,I: 1.00 +/- 0.22, II: 1.71 +/- 0.18, vascular growth s
core p = 0.001). Resting myocardial blood flow (colored microspheres) was n
ot significantly impaired in any group. However, maximum blood flow (adenos
ine) was reduced in ischemic territories and did not improve in GF(m)-treat
ed hearts. GF(m), a multiple growth factor mixture, is a potent angiogenic
agent that stimulates large vessel growth. Although blood flow did not impr
ove during maximal vasodilatory stress, large intramyocardial collateral ve
ssels developed and angiographic visualization of the occluded distal LAD i
mproved significantly. The use of multiple growth factors may be an effecti
ve strategy for therapeutic angiogenesis provided a more effective delivery
strategy is devised that can achieve improved maximum blood flow potential
.